Education
About Us
Working with TipRanks
Follow Us
Brainsway Ltd (BWAY)
NASDAQ:BWAY
BWAY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.61 - $13.66
Previous CloseN/A
Volume9.67K
Average Volume (3M)47.83K
Market Cap
$219.19M
Enterprise Value$112.38M
Total Cash (Recent Filing)$71.60M
Total Debt (Recent Filing)$5.57M
Price to Earnings (P/E)54.7
Beta1.40
Next Earnings
Aug 13, 2025EPS Estimate
0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding18,898,308
10 Day Avg. Volume20,073
30 Day Avg. Volume47,826
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue2.59
Enterprise Value/Gross Profit3.47
Enterprise Value/Ebitda18.50
Forecast
1Y Price Target
$15.33Price Target Upside29.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBrainsWay recorded $11.4M in top-line revenue, beating analyst forecast of $10.7M.
Product EfficacyThe accelerated Deep TMS protocol resulted in outcomes comparable to the standard once-daily TMS protocol while requiring considerably fewer visits to the clinic.
Regulatory ApprovalsBrainsWay received expanded FDA labeling for Deep TMS to treat late-life depression, increasing the upper age limit from 68 to 86 years, thus broadening the availability of Deep TMS therapy.
Bears Say
Market RisksRisks include slower-than-projected market uptake of Deep TMS systems and failure to expand reimbursement and market access.
Strategic Expansion RisksRisks include inability to advance in other indications.
Brainsway News
BWAY FAQ
What was Brainsway Ltd’s price range in the past 12 months?
Brainsway Ltd lowest stock price was $6.61 and its highest was $13.65 in the past 12 months.
What is Brainsway Ltd’s market cap?
Brainsway Ltd’s market cap is $219.19M.
When is Brainsway Ltd’s upcoming earnings report date?
Brainsway Ltd’s upcoming earnings report date is Aug 13, 2025 which is in 5 days.
How were Brainsway Ltd’s earnings last quarter?
Brainsway Ltd released its earnings results on May 13, 2025. The company reported $0.02 earnings per share for the quarter, missing the consensus estimate of $0.022 by -$0.002.
Is Brainsway Ltd overvalued?
According to Wall Street analysts Brainsway Ltd’s price is currently Undervalued.
Does Brainsway Ltd pay dividends?
Brainsway Ltd does not currently pay dividends.
What is Brainsway Ltd’s EPS estimate?
Brainsway Ltd’s EPS estimate is 0.03.
How many shares outstanding does Brainsway Ltd have?
Brainsway Ltd has 18,898,308 shares outstanding.
What happened to Brainsway Ltd’s price movement after its last earnings report?
Brainsway Ltd reported an EPS of $0.02 in its last earnings report, missing expectations of $0.022. Following the earnings report the stock price went up 11.099%.
Which hedge fund is a major shareholder of Brainsway Ltd?
Currently, no hedge funds are holding shares in BWAY
Brainsway Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.33 (29.59% Upside)
$15.33 (29.59% Upside)
Blogger Sentiment
Bullish
BWAY Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 12.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 2.8%
Last 30 Days ▲ 2.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
71.84%
12-Months-Change
Fundamentals
Return on Equity
7.41%
Trailing 12-Months
Asset Growth
53.81%
Trailing 12-Months
Company Description
Brainsway Ltd
Brainsway Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States, Europe, Israel, and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company primarily serves doctors, hospitals, and medical centers in the field of psychiatry. Brainsway Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.
BWAY Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong growth in both revenue and system shipments, indicating robust demand for BrainsWay's Deep TMS systems. The company is making significant strides in clinical advancements and maintains a strong financial position with positive guidance for the year. However, increased operating expenses and potential geopolitical risks are concerns that need monitoring.View all BWAY earnings summariesBWAY Stock 12 Month Forecast
Average Price Target
$15.33
▲(29.59% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.86% Mutual Funds
0.87% Other Institutional Investors
97.12% Public Companies and
Individual Investors